 NEW YORK and CLEVELAND, July 23, 2021 GLOBE NEWSWIRE -- Abeona Therapeutics Inc. Nasdaq: ABEO, a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITALTM study of its investigational EB-101 treatment for recessive dystrophic epidermolysis bullosa RDEB at UMass Memorial Medical Center in Worcester, MA. 